Publication
Article
Participating Faculty: Economic Evaluation of a Fluocinolone Acetonide Intravitreal Implant for Patients With DME Based on the FAME Study
Author(s):
This supplement to The American Journal of Managed Care describes an economic evaluation of a fluocinolone acetonide (FAc) intravitreal implant for patients with diabetic macular edema (DME). The results show that from both a healthcare and societal perspective, the FAc implant is a costeffective treatment for patients with DME who have received a previous course of a corticosteroid with no clinically significant rise in intraocular pressure.This supplement was sponsored by Alimera Sciences.
Faculty
Antonio Cutino, BA
Vice President
Medical Affairs
Alimera Sciences
Alpharetta, Georgia
Kenneth Green, PhD
Chief Scientific Officer
Alimera Sciences
Alpharetta, Georgia
Robyn Kendall, PGDip, BSc
Health Economist
ICON Commercialization and Outcomes
Vancouver, BC, Canada
Peter T. Moore, MSc
Lead Health Economist
ICON Health Economics and Epidemiology
Sydney, Australia
Christopher Zachary, MBA
Vice President
US Managed Markets
Alimera Sciences
Alpharetta, Georgia
Faculty Disclosures
These faculty report relationships with the following organizations:
Antonio Cutino, BA
Employment and stock ownership: Alimera Sciences
Kenneth Green, PhD
Employment and stock ownership: Alimera Sciences
Peter T. Moore, MSc
Consultant and receipt of payment for involvement in preparation of manuscript: Alimera Sciences
Christopher Zachary, MBA
Employment and stock ownership: Alimera Sciences
Robyn Kendall, PGDip, BSc, reports no relationships or financial interests with any entity that would pose a conflict of interest with the
subject matter of this supplement.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
